Astrazeneca Phar
Drug Manufacturers - Specialty & Generic · ASTRAZEN
Mid CapHealthcareMature Stable
Dr. Sanjeev Kumar Panchal
Managing Director · Pragmatic
Company DNA
Bureaucratic
About
Astrazeneca Phar is a Mid Cap company in the Healthcare sector, listed on NSE as ASTRAZEN. With a market cap of ₹22K Cr and revenue of ₹2K Cr, it is currently in the Mature Stable phase. Known for its Bureaucratic culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Global MNC subsidiary with deep focus on compliance, regulatory adherence, and standardized global processes typical of large pharma. Its strategic mandate: As a stable pharma player, the firm requires pragmatic leadership focused on deepening the R&D pipeline and navigating complex regulatory environments.
FAQ
What kind of company is Astrazeneca Phar?
Astrazeneca Phar is a Mid Cap Healthcare company (ASTRAZEN) in the Mature Stable phase with a market cap of ₹22K Cr. It is classified as Bureaucratic in culture.
What is Astrazeneca Phar's culture and work environment like?
Astrazeneca Phar has a Bureaucratic culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2B-Enterprise. Global MNC subsidiary with deep focus on compliance, regulatory adherence, and standardized global processes typical of large pharma.
Who leads Astrazeneca Phar?
Astrazeneca Phar is led by Dr. Sanjeev Kumar Panchal (Managing Director), a Pragmatic leader with 26 years of experience.
What are Astrazeneca Phar's financials?
Astrazeneca Phar reported revenue of ₹2K Cr in FY25 with a 5-year revenue CAGR of 28.6%. Operating margin: 12.5%. Market cap: ₹22K Cr.
Culture & Strategy
CultureBureaucratic
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeSteady Employer
BrandTrusted
LifecycleMature Stable
Global MNC subsidiary with deep focus on compliance, regulatory adherence, and standardized global processes typical of large pharma.
Mandate
As a stable pharma player, the firm requires pragmatic leadership focused on deepening the R&D pipeline and navigating complex regulatory environments.
As a stable pharma player, the firm requires pragmatic leadership focused on deepening the R&D pipeline and navigating complex regulatory environments.
Financials
Revenue FY25₹2K Cr
PAT FY25₹116 Cr
Rev CAGR 5Y28.6%
OPM12.5%
NPM6.8%
ROE15%
ROCE26.4%
P/E104.2
Fwd P/E—
P/B26.3
D/E4.4
Mkt Cap₹22K Cr
Promoter81.6%
Institutional7.1%
Similar Culture
Could You Lead Astrazeneca Phar?
Take the Genome Benchmark →